Media Coverage

Boehringer tackles swine influenza strains with US launch of Ingelvac Provenza

Mar 08, 2018 - Animal Pharm
By Joseph Harvey
Animal Pharm
March 8, 2018

Boehringer Ingelheim Vetmedica has introduced Ingelvac Provenza to protect against the influenza A virus in swine (IAV-S).

This is the first live attenuated influenza vaccine for growing pigs to be commercialized in the US. The product offers an increased level of protection against swine influenza virus strains H1N2 and H3N2.

Around 70% of growing pigs in the US suffer from IAV-S, which is one of the country's top three most common swine diseases. Boehringer's new vaccine allows pigs as young as day one to be vaccinated. The company said the new product fulfils an unmet need with its proven efficacy, safety, flexibility of timing and method of administration.

The vaccine's intranasal route of administration provides a direct means of protection at the site of IAV-S infection.

Christa Goodell, technical manager for the Boehringer US swine business, said: "Vaccinating pigs as young as one-day old provides protection before pigs are most vulnerable. Ingelvac Provenza offers cross-protection against multiple IAV-S strains and decreases nasal shedding, thereby reducing transmission within the population."

Del Birkhofer, head of the US swine business and Newport Laboratories, added: "IAV-S can have a widespread impact on the health of the pig population and subsequently, the productivity and profitability for producers.

"Studies have shown that uncomplicated IAV-S infection can lead to an estimated loss of more than $3 per pig, and when IAV-S is present with concurrent infections, the loss can be greater than $10 per pig."

Boehringer gained certain US vaccine capabilities when it purchased Merial last year. Merial itself acquired Newport Laboratories in 2012. Newport's particular expertise is in autogenous vaccines in the US cattle and swine production markets.

As well as this latest introduction to the Boehringer pig vaccine portfolio, the firm also sells Ingelvac ERY-ALC, Ingelvac HP-1, Ingelvac PRRS ATP and Ingelvac PRRS MLV in the US. The company also sells its FLEX family of six swine vaccines. In fact, Ingelvac CircoFlex is the company's top-selling product for livestock.

Last year, Boehringer pre-empted increased demand for veterinary vaccines by spending $80 million on expanding its two of its US facilities.

Reprinted with permission of Animal Pharm News




News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum